BOLT
Price
$4.90
Change
+$0.27 (+5.83%)
Updated
Jun 4, 12:32 PM (EDT)
Capitalization
8.9M
69 days until earnings call
Intraday BUY SELL Signals
DNA
Price
$9.90
Change
+$1.17 (+13.40%)
Updated
Jun 4, 01:07 PM (EDT)
Capitalization
570.28M
63 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BOLT vs DNA

Header iconBOLT vs DNA Comparison
Open Charts BOLT vs DNABanner chart's image
BOLT vs DNA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BOLT vs. DNA commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BOLT is a Hold and DNA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 04, 2026
Stock price -- (BOLT: $4.63 vs. DNA: $8.73)
Brand notoriety: BOLT and DNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BOLT: 89% vs. DNA: 107%
Market capitalization -- BOLT: $8.9M vs. DNA: $570.28M
BOLT [@Biotechnology] is valued at $8.9M. DNA’s [@Biotechnology] market capitalization is $570.28M. The market cap for tickers in the [@Biotechnology] industry ranges from $108.72B to $0. The average market capitalization across the [@Biotechnology] industry is $1.83B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BOLT’s FA Score shows that 1 FA rating(s) are green whileDNA’s FA Score has 1 green FA rating(s).

  • BOLT’s FA Score: 1 green, 4 red.
  • DNA’s FA Score: 1 green, 4 red.
According to our system of comparison, DNA is a better buy in the long-term than BOLT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BOLT’s TA Score shows that 2 TA indicator(s) are bullish while DNA’s TA Score has 5 bullish TA indicator(s).

  • BOLT’s TA Score: 2 bullish, 6 bearish.
  • DNA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, DNA is a better buy in the short-term than BOLT.

Price Growth

BOLT (@Biotechnology) experienced а -12.39% price change this week, while DNA (@Biotechnology) price change was +0.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.46%. For the same industry, the average monthly price growth was +0.40%, and the average quarterly price growth was +6.17%.

Reported Earning Dates

BOLT is expected to report earnings on Aug 12, 2026.

DNA is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Biotechnology (-0.46% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNA($570M) has a higher market cap than BOLT($8.9M). DNA YTD gains are higher at: 5.054 vs. BOLT (-15.326). BOLT has higher annual earnings (EBITDA): -43.24M vs. DNA (-251.5M). DNA has more cash in the bank: 373M vs. BOLT (31.9M). BOLT has less debt than DNA: BOLT (23.6M) vs DNA (411M). DNA has higher revenues than BOLT: DNA (151M) vs BOLT (5.2M).
BOLTDNABOLT / DNA
Capitalization8.9M570M2%
EBITDA-43.24M-251.5M17%
Gain YTD-15.3265.054-303%
P/E RatioN/AN/A-
Revenue5.2M151M3%
Total Cash31.9M373M9%
Total Debt23.6M411M6%
TECHNICAL ANALYSIS
Technical Analysis
BOLTDNA
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
87%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 8 days ago
74%
Bullish Trend 8 days ago
83%
Declines
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 4 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
BOLT
Daily Signal:
Gain/Loss:
DNA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FICDX84.41N/A
N/A
Fidelity Canada
CSECX17.36N/A
N/A
Calvert Equity C
ETAMX15.50N/A
N/A
Eventide Balanced Fund Class A
CCOYX300.14N/A
N/A
Columbia Seligman Tech & Info Inst3
BVOIX12.53N/A
N/A
Barrow Hanley US Value Opportunities I

DNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNA has been loosely correlated with VCYT. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DNA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNA
1D Price
Change %
DNA100%
-6.43%
VCYT - DNA
58%
Loosely correlated
+1.95%
RXRX - DNA
49%
Loosely correlated
-3.88%
ABCL - DNA
48%
Loosely correlated
-6.85%
AXON - DNA
44%
Loosely correlated
-1.76%
ABSI - DNA
43%
Loosely correlated
-6.46%
More